Proteomic Analysis Highlights the Impact of the Sphingolipid Metabolizing Enzyme β-Galactosylceramidase on Mitochondrial Plasticity in Human Melanoma
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25053062 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Davide Capoferri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy. Hauptthemen laut MEDLINE: Galactosylceramidase, Melanoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, PNRR M4C2 finanziato dall'Unione Europea-NextGenerationEU, Consorzio Universitario Biotecnologie.
Abstract (Originalsprache)
Mitochondrial plasticity, marked by a dynamism between glycolysis and oxidative phosphorylation due to adaptation to genetic and microenvironmental alterations, represents a characteristic feature of melanoma progression. Sphingolipids play a significant role in various aspects of cancer cell biology, including metabolic reprogramming. Previous observations have shown that the lysosomal sphingolipid-metabolizing enzyme β-galactosylceramidase (GALC) exerts pro-oncogenic functions in melanoma. Here, mining the cBioPortal for a Cancer Genomics data base identified the top 200 nuclear-encoded genes whose expression is negatively correlated with GALC expression in human melanoma. Their categorization indicated a significant enrichment in Gene Ontology terms and KEGG pathways related to mitochondrial proteins and function. In parallel, proteomic analysis by LC-MS/MS of two GALC overexpressing human melanoma cell lines identified 98 downregulated proteins when compared to control mock cells. Such downregulation was confirmed at a transcriptional level by a Gene Set Enrichment Analysis of the genome-wide expression profiling data obtained from the same cells. Among the GALC downregulated proteins, we identified a cluster of 42 proteins significantly associated with GO and KEGG categorizations related to mitochondrion and energetic metabolism. Overall, our data indicate that changes in GALC expression may exert a significant impact on mitochondrial plasticity in human melanoma cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
- Department of Translational Medicine, University of Piemonte Orientale, 13100 Novara, Italy.
- Consorzio Interuniversitario Biotecnologie (CIB), Unit of Brescia, 25123 Brescia, Italy.
ORCID-Profile: Davide Capoferri, Marcello Manfredi, Marco Presta
Förderung
- Italian Association for Cancer Research
- PNRR M4C2 finanziato dall'Unione Europea-NextGenerationEU
- Consorzio Universitario Biotecnologie
- Associazione Italiana per la Ricerca sul Cancro (AIRC)
- dall’Unione Europea-NextGenerationEU
- Department of Excellence—DIMET, Università del Piemonte Orientale
- Fondazione Umberto Veronesi fellowship
Zitieren
APA
Capoferri, D., Mignani, L., Manfredi, M., & Presta, M. (2024). Proteomic Analysis Highlights the Impact of the Sphingolipid Metabolizing Enzyme β-Galactosylceramidase on Mitochondrial Plasticity in Human Melanoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25053062
Vancouver
Capoferri D, Mignani L, Manfredi M, Presta M. Proteomic Analysis Highlights the Impact of the Sphingolipid Metabolizing Enzyme β-Galactosylceramidase on Mitochondrial Plasticity in Human Melanoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25053062
BibTeX
@article{Capoferri2024,
author = {Capoferri, Davide and Mignani, Luca and Manfredi, Marcello and Presta, Marco},
title = {Proteomic Analysis Highlights the Impact of the Sphingolipid Metabolizing Enzyme β-Galactosylceramidase on Mitochondrial Plasticity in Human Melanoma},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25053062}
}
EUVIMED